Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Sponsor: AB Science
This PHASE3 trial investigates Pancreatic Cancer and is currently completed. AB Science leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jun 2018 — Dec 2018 [monthly]
Unknown Status PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AB Science
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Antony, France , Arad, Romania , Atlanta, United States , Avignon, France , Baia Mare, Romania , Beirut, Lebanon , Besançon, France , Bordeaux, France , Brest, France and 44 more locations